Search:

HCRN launches new website

Hoosier Cancer Research Network (HCRN) launched an updated website today...

HCRN-GU16-260 (1)

Correlative analysis from HCRN GU16-260 study published in Cancer Discovery

February 27, 2025
Researchers participating in the Hoosier Cancer Research Network GU16-260 study...
Researchers participating in the Hoosier Cancer Research Network GU16-260 study have published a correlative analysis in Cancer Discovery. The analysis, led by David A. Braun, MD, PhD, of Yale Cancer Center; Catherine J. Wu, MD, of the Dana-Farber Cancer Institute; and Michael B. Atkins, MD, of Georgetown Lombardi Comprehensive Cancer Center, found that the presence of tertiary lymphoid structures and exhausted tissue-resident T cells determines clinical response to PD-1 blockade in renal cell carcinoma. Congratulations to all co-authors and study teams...
Noah Hahn

Five HCRN studies presented at ASCO GU 2025, with HCRN-GU16-243 as a rapid oral abstract

February 13, 2025
Hoosier Cancer Research Network (HCRN) is set to participate in...
Hoosier Cancer Research Network (HCRN) is set to participate in ASCO GU 2025 in San Francisco from February 13-15, 2025, with HCRN-GU16-243 being presented as a Rapid Oral Abstract, and several other studies as poster presentations.
Brian IIB Feature Photo

HCRN-LUN21-497 presented at SITC 2024

January 28, 2025
A Hoosier Cancer Research Network study, HCRN-LUN21-497, titled, “Results from...
A Hoosier Cancer Research Network study, HCRN-LUN21-497, titled, “Results from a phase II study of GT103 in combination with pembrolizumab in refractory, metastatic non-small cell lung cancer,” was presented at SITC 2024 by Jeffrey Clarke, MD, of Duke University.
Untitled design (23)

HCRN-GI23-643 presented at ASCO GI 2025

January 22, 2025
HCRN-GI23-643, titled, “Randomized Trial of Regorafenib in Combination with Pembrolizumab...
HCRN-GI23-643, titled, “Randomized Trial of Regorafenib in Combination with Pembrolizumab or Pembrolizumab Monotherapy for Patients with MSI-H Colorectal Cancer,” will be presented as a Trials in Progress poster at the American Society of Clinical Oncology® (ASCO) Gastrointestinal Cancers Symposium 2025 in San Francisco. This study is led by Ibrahim Sahin, MD, of UPMC Hillman Cancer Center.
Noah Hahn

HCRN-GU16-243 presented at SUO 2024

December 20, 2024
A correlative study related to the Hoosier Cancer Research Network...
A correlative study related to the Hoosier Cancer Research Network (HCRN) clinical trial, HCRN-GU16-243, titled, “A Phase 1 Trial of Durvalumab in Combination with Bacillus Calmette-Guerin (BCG) or External Beam Radiation Therapy in Patients with BCG-unresponsive Non-muscle-Invasive Bladder Cancer: The Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER Study,” was presented at SUO 2024 by Noah Hahn, MD, of Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center.
Dr.-Le

HCRN Non-Small Cell Lung Cancer Study Published in Journal of Clinical Oncology

December 10, 2024
A Hoosier Cancer Research Network (HCRN) study, HCRN-LUN18-335, led by...
A Hoosier Cancer Research Network (HCRN) study, HCRN-LUN18-335, led by Xiuning Le, MD, PhD, of the University of Texas MD Anderson Cancer Center, was published in the Journal of Clinical Oncology on October 8, 2024. The article is titled, “A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor–Naïve EGFR-Mutant Metastatic Non–Small Cell Lung Cancer (RAMOSE trial).” Congratulations to all co-authors and study teams whose hard work led to this publication!
Assi Story Featured Image (1)

Rita Assi, MD, Elected President-Elect of Indiana Oncology Society 2024-2026 Board of Directors

October 11, 2024
Hoosier Cancer Research Network congratulates Rita Assi, MD, on her...
Hoosier Cancer Research Network congratulates Rita Assi, MD, on her election as the President-Elect of the Indiana Oncology Society 2024-2026 Board of Directors. Dr. Assi is a board member of HCRN and is assistant professor of clinical medicine at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.
Untitled design (17)

40 Years of friendship and collaboration: A conversation with HCRN co-founders Pat Loehrer and Bill Fisher

October 4, 2024
Hoosier Cancer Research Network (HCRN) recently joined two of our...
Hoosier Cancer Research Network (HCRN) recently joined two of our visionary founders, Patrick J. Loehrer, MD, and William B. Fisher, MD, as they shared stories spanning their 40 years of involvement with HCRN, formerly known as Hoosier Oncology Group, or affectionately, the “HOG.”
download

HCRN-LUN18-357 accepted to World Conference on Lung Cancer

August 28, 2024
A Hoosier Cancer Research Network trial, HCRN-LUN18-357, titled “P1.08D.03 Induction...
A Hoosier Cancer Research Network trial, HCRN-LUN18-357, titled “P1.08D.03 Induction Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-Small Cell Lung Cancer (NSCLC)” has been accepted as a poster presentation and will be presented at the World Conference on Lung Cancer Meeting on September 8, 2024 from 12:00 pm-2:00 pm.
Abstracts (300 x 173 px)

HCRN 2023-24 Manuscripts & Meeting Abstracts

August 1, 2024
  Hoosier Cancer Research Network is happy to celebrate the...
  Hoosier Cancer Research Network is happy to celebrate the research accomplishments of our members over the past year. Congratulations to all researchers and study teams whose hard work produced 23 journal manuscripts and meeting abstracts between July 1, 2023, and June 30, 2024!